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ABSTRACT Dicer enzymes process virus-specific double-stranded RNA (dsRNA) into
small interfering RNAs (siRNAs) to initiate specific antiviral defense by related RNA
interference (RNAi) pathways in plants, insects, nematodes, and mammals. Antiviral
RNAi in Caenorhabditis elegans requires Dicer-related helicase 1 (DRH-1), not found
in plants and insects but highly homologous to mammalian retinoic acid-inducible
gene I (RIG-I)-like receptors (RLRs), intracellular viral RNA sensors that trigger innate
immunity against RNA virus infection. However, it remains unclear if DRH-1 acts
analogously to initiate antiviral RNAi in C. elegans. Here, we performed a forward ge-
netic screen to characterize antiviral RNAi in C. elegans. Using a mapping-by-
sequencing strategy, we uncovered four loss-of-function alleles of drh-1, three of
which caused mutations in the helicase and C-terminal domains conserved in RLRs.
Deep sequencing of small RNAs revealed an abundant population of Dicer-dependent
virus-derived small interfering RNAs (vsiRNAs) in drh-1 single and double mutant ani-
mals after infection with Orsay virus, a positive-strand RNA virus. These findings pro-
vide further genetic evidence for the antiviral function of DRH-1 and illustrate that
DRH-1 is not essential for the sensing and Dicer-mediated processing of the viral
dsRNA replicative intermediates. Interestingly, vsiRNAs produced by drh-1 mutants
were mapped overwhelmingly to the terminal regions of the viral genomic RNAs, in
contrast to random distribution of vsiRNA hot spots when DRH-1 is functional. As
RIG-I translocates on long dsRNA and DRH-1 exists in a complex with Dicer, we pro-
pose that DRH-1 facilitates the biogenesis of vsiRNAs in nematodes by catalyzing
translocation of the Dicer complex on the viral long dsRNA precursors.
IMPORTANCE The helicase and C-terminal domains of mammalian RLRs sense in-
tracellular viral RNAs to initiate the interferon-regulated innate immunity against
RNA virus infection. Both of the domains from human RIG-I can substitute for the
corresponding domains of DRH-1 to mediate antiviral RNAi in C. elegans, sug-
gesting an analogous role for DRH-1 as an intracellular dsRNA sensor to initiate
antiviral RNAi. Here, we developed a forward genetic screen for the identification
of host factors required for antiviral RNAi in C. elegans. Characterization of four
distinct drh-1 mutants obtained from the screen revealed that DRH-1 did not
function to initiate antiviral RNAi. We show that DRH-1 acted in a downstream
step to enhance Dicer-dependent biogenesis of viral siRNAs in C. elegans. As
mammals produce Dicer-dependent viral siRNAs to target RNA viruses, our find-
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ings suggest a possible role for mammalian RLRs and interferon signaling in the
biogenesis of viral siRNAs.
KEYWORDS Caenorhabditis elegans, DRH-1, RNA interference, antiviral defense
Diverse eukaryotic hosts recognize and process virus-specific double-stranded RNA(dsRNA) into small interfering RNAs (siRNAs), which subsequently direct specific
antiviral immunity by RNA interference (RNAi) (1, 2). The virus-derived siRNAs (vsiRNAs)
are products of the Dicer family of dsRNA-specific endoribonucleases and therefore
exhibit several unique biochemical properties. For example, vsiRNAs are 21 to 24
nucleotides (nt) in length, contain monophosphates at the 5= ends, and form perfectly
base-paired RNA duplexes with 2-nt 3= overhangs. In addition to serving as a molecular
marker for the induction of antiviral RNAi, vsiRNAs also function as the specificity
determinants of the antiviral immunity after they are assembled with an Argonaute
protein and cofactors into RNA-induced silencing complex (RISC) (1, 2).
Recent studies have established Caenorhabditis elegans as a small-animal model for
antiviral RNAi studies (3–5). C. elegans has a short life cycle with a large brood size and
is particularly amenable to genetic analyses at the organismal level. Antiviral RNAi was
first shown to inhibit the replication of Flock House virus (FHV) launched from an
integrated transgene in the worm genome and the infection of primary worm cells with
vesicular stomatitis virus (VSV) (6–8). FHV is a member of the Nodaviridae, which include
viruses with a bipartite positive-strand RNA genome. VSV contains a nonsegmented
negative-strand RNA genome. However, neither FHV nor VSV naturally infects C. el-
egans. Orsay virus (OrV), the first virus known to naturally infect C. elegans in the wild,
was reported in 2011 by a collaborative team among the Felix, Miska, and Wang
laboratories (9). OrV and the related Le Blanc and Santeuil viruses that infect Caeno-
rhabditis briggsae all contain a closely related bipartite positive-strand RNA genome
most similar to that of nodaviruses (9–13). Notably, genetic studies have shown that
FHV, VSV, and OrV are all targeted in C. elegans by a conserved antiviral RNAi pathway
(9, 14–18) mechanistically similar to exogenous RNAi triggered by long dsRNA, char-
acterized extensively since its discovery in 1998 (19).
In exogenous RNAi, long dsRNA is processed into siRNAs by the single nematode
Dicer in complex with dsRNA-binding protein RDE-4 (20, 21). These Dicer-dependent
primary siRNAs are predominantly 23 nt long and do not show nucleotide preferences
at the 5= termini. After loading into RISC containing Argonaute RDE-1, these primary
siRNAs recognize the target RNA via base-pairing and recruit cellular RNA-dependent
RNA polymerase (RdRP) RRF-1 in complex with Dicer-related helicase 3 (DRH-3) to
synthesize antisense secondary siRNAs in somatic cells (22–24). Known also as 22G
siRNAs, mature secondary siRNAs are predominantly 22 nt long, contain triphosphates
at the 5= ends, overwhelmingly prefer guanosine as the 5=-terminal nucleotide, are
much more abundant than the primary siRNAs, and are loaded into worm-specific
Argonaute proteins to guide target RNA clearance (23, 25). Secondary siRNAs also play
an essential role in RNAi in plants, although they are the products of Dicer and thus
have the same biochemical properties as the primary siRNAs (26, 27). Antiviral RNAi
triggered by OrV infection in C. elegans is also associated with the production of both
the primary and secondary vsiRNAs (14, 17). Defective antiviral RNAi in rde-1, rrf-1, and
drh-3 mutant worms is correlated with the loss of the viral 22G siRNAs even though the
23-nt primary vsiRNAs processed by Dicer from viral dsRNA replicative intermediates
are highly abundant (14, 17). Consistently, FHV RNA replication induces accumulation
of highly abundant 23-nt primary vsiRNAs in rde-1 mutant worms (28, 29). Similarly to
exogenous RNAi, therefore, 22G siRNAs are essential for antiviral RNAi.
Intriguingly, Dicer-related helicase 1 (DRH-1) is essential for antiviral RNAi but is
largely dispensable for exogenous RNAi (7, 14, 17), revealing a specific genetic require-
ment for antiviral RNAi. DRH-1 and DRH-3 are highly homologous to the family of
mammalian RIG-I-like receptors (RLRs) (20), which act as intracellular viral RNA sensors
to initiate the interferon-regulated innate immunity against RNA virus infection in
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mammals (30, 31). RLRs, which are found in neither fruit flies nor plants, include three
members in mammals: retinoic acid-inducible gene I (RIG-I), melanoma differentiation-
associated protein 5 (MDA5), and Laboratory of Genetics and Physiology 2 (LGP2). The
central helicase domain and the C-terminal regulatory domain of RLRs are required for
the sensing of specific intracellular viral RNAs, including viral dsRNA (30, 31). RIG-I and
MDA5, but not LGP2, contain an N-terminal tandem caspase activation and recruitment
domain (CARD) necessary for downstream innate immune signaling upon the detection
of the intracellular viral RNA, leading to the production of type I interferons and the
expression of numerous interferon-stimulated genes. DRH-1 and DRH-3 as well as
DRH-2 share sequence homology with mammalian RLRs in the central helicase and
C-terminal domains (7, 20). However, the N-terminal domain conserved in DRH-1 and
DRH-3 shares no sequence similarity with CARD and is absent in DRH-2. The helicase
domains of RLRs and DRHs are closely related to that found in Dicer proteins encoded
by diverse eukaryotes (20, 32, 33). Pyle and colleagues have recently designated these
proteins duplex RNA-activated ATPases since their helicase/ATPase domains contain a
unique -helical insertion domain (Hel2i) and lack dsRNA unwinding activity of the RNA
helicases (34). It is known that RIG-I translocates along dsRNA during the activation of
innate immune signaling in a process powered by ATP hydrolysis (35).
DRH-1 was initially identified as a component in the complex with both Dicer and
RDE-4 (20). The antiviral role of DRH-1 was discovered because FHV replicated to
significantly enhanced levels after depletion of drh-1 mRNA or in worm mutants
homozygous for a loss-of-function drh-1 allele (7). A natural antiviral function of DRH-1
was recently illustrated elegantly by the identification of a 159-bp deletion polymor-
phism in the drh-1 gene of wild C. elegans isolates exhibiting defective antiviral RNAi
against OrV infection using a genome-wide association study (14). The accumulation of
FHV-specific vsiRNAs in drh-1 mutant worms is readily detectable by Northern blot
hybridization (7, 17). Notably, efficient silencing of cellular genes targeted in trans by
complementary vsiRNAs induced by FHV replication is abolished in rde-1 and rrf-1
mutants but not in drh-1 mutant worms (15, 17). Thus, drh-1 mutant worms produce
functional secondary vsiRNAs possibly at reduced levels that are sufficient to inhibit the
expression of cellular genes but not the replication of viral genomic RNAs. These
findings suggest that DRH-1 acts downstream of the biogenesis of vsiRNAs in antiviral
RNAi (7, 17).
A recent study has comprehensively characterized the populations of the primary
and secondary vsiRNAs produced by a panel of wild-type and mutant C. elegans strains
after infection with OrV (14). Consistent with the previous study (7), drh-1 mutants
display no difference in endogenous 22G siRNAs mapping antisense to protein-
encoding genes (14). OrV-infected drh-1 mutant worms indeed accumulate low levels
of the secondary vsiRNAs (14), which appears to explain why cellular genes are silenced
by vsiRNAs in drh-1 mutant worms (17). However, the size distribution of the total
virus-derived small RNAs mapped to the RNA genome of OrV suggested a severe defect
in the biogenesis of the 23-nt primary vsiRNAs in drh-1 mutant worms (14). Interest-
ingly, both the ATPase and C-terminal domains of human RIG-I can substitute for the
corresponding domains of DRH-1 to mediate antiviral RNAi in C. elegans (17). Moreover,
the KWK motif conserved in the C-terminal domains of RIG-I and DRH-1 is required for
antiviral RNAi in C. elegans (17). These findings suggest a new model for DRH-1 function
in which, similarly to mammalian RLRs, DRH-1 acts as an intracellular dsRNA sensor to
initiate antiviral RNAi in C. elegans (14).
In this study, we developed an organism-level, unbiased screen for the genetic
dissection of the antiviral RNAi pathway in C. elegans. Using chemical mutagenesis and
a mapping approach based on whole-genome sequencing, we isolated and cloned four
novel mutant alleles of drh-1 located in the conserved ATPase and C-terminal domains
as well as in the worm-specific N-terminal domain. Deep sequencing of small RNAs
revealed accumulation of Dicer-dependent vsiRNAs targeting OrV genomic RNAs in
multiple drh-1 single and double mutant animals. Our findings show that, in contrast to
mammalian RLRs, DRH-1 does not act as the receptor to initiate antiviral RNAi in
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C. elegans. We discuss a model in which a predicted dsRNA translocase activity of DRH-1
is involved in the processing of viral dsRNA replicative intermediates by the DCR-1/
RDE-4/DRH-1 complex.
RESULTS
Identification of C. elegans mutants with enhanced virus susceptibility from
forward genetic screens. We constructed a C. elegans strain carrying a single-copy,
heat-inducible transgene that directed transcription of a self-replicating FHV RNA1
derivative, FR1gfp, described previously (see Fig. S1A in the supplemental material) (7).
The genomic RNA1 of FHV replicates to high levels in C. elegans in the absence of the
genomic RNA2, which encodes the capsid protein, because of potent suppression of
antiviral RNAi by the viral suppressor of RNAi (VSR) B2 protein, expressed from the
subgenomic RNA3 produced after RNA1 replication (6). The absence of B2 expression
from FR1gfp renders this RNA1 derivative highly susceptible to antiviral RNAi, which
effectively inhibits the expression of enhanced green fluorescent protein (GFP) in place
of B2 (7).
As expected, none of the wild-type N2 animals exhibited any visible GFP expression
after the induction of FR1gfp replication (Fig. 1A). In contrast, strong GFP expression
was associated with FR1gfp replication after the viral transgene was introduced into
C. elegans mutants defective in antiviral RNAi, either in the whole body [e.g., drh-
1(tm1329)] or in the pharynx [e.g., rde-1(ne219)] (Fig. 1B). Northern blot analysis further
revealed that while both RNA1 and RNA3 of FR1gfp accumulated to high levels in rde-1,
rde-4, and drh-1mutant animals, neither viral RNA was detectable in the N2 background
(Fig. S1C). As described previously for N2 worms carrying a multicopy FR1gfp transgene
array (7), therefore, both the replication of the recombinant FHV RNA1 and the viral GFP
expression from the single-copy FR1gfp transgene in the new worm strain were
potently inhibited by antiviral RNAi, establishing the N2;FR1gfp worm as a model for the
genetic characterization of the antiviral RNAi pathway.
We subjected N2;FR1gfp young adults to standard ethyl methanesulfonate (EMS)-
induced mutagenesis (36) and screened approximately 284,000 haploid genomes.
When the mutagenized F2 generation reached the L4 stage, FR1gfp replication was
induced by heat treatment, and 48 h later, worms were screened for GFP expression.
Single worms expressing GFP were transferred to individual plates to establish inde-
FIG 1 Isolation of mutants defective in antiviral immunity. (A) Synchronized L1 wild-type (N2) and
mutant animals carrying the phsp-16.41::FR1gfp transgene were plated and heat induced for 4 h at 34°C
at the L4 stage. GFP was visualized by fluorescence microscopy 48 h after heat induction. (B) Northern
blot detection of OrV RNA1 accumulation in N2 and the isolated mutants (designated ucr) grouped
according to their susceptibility (left) or resistance (right) to exogenous RNAi, using known mutants as
controls.
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pendent F2 mutant lines. Although most of the identified mutant animals did not
survive, we isolated 13 viable mutants that reproducibly failed to suppress GFP expres-
sion from FR1gfp in subsequent generations (Fig. 1A and Fig. S1B). However, we noted
that the phenotypic penetrance of GFP expression was less than 100% in all of the
isolated mutants.
We first determined if the isolated worm mutants were defective either in antiviral
defense against OrV infection or in experimentally induced RNAi. N2 animals are
resistant to OrV (5), so that the accumulation of OrV RNAs is not readily detectable by
Northern blotting (Fig. 1B). We found that all of the 13 mutants were more susceptible
to OrV since they reproducibly supported high-level replication of OrV (Fig. 1B).
Interestingly, five of the 13 mutants, the ucr9, ucr11, ucr12, ucr13, and ucr14 mutants,
became resistant to exogenous RNAi against both genes (pop-1 and pos-1) expressed
mainly in the germline (Fig. 2C), suggesting defective antiviral RNAi in these mutants.
Resistance to exogenous RNAi targeting two somatic genes, dpy-7 and unc-22, was also
detected in these RNAi-defective mutants, except the ucr12 mutant (Fig. 2A and B).
However, the remaining eight mutants, the ucr2 to ucr8 and ucr10 mutants, supported
efficient exogenous RNAi targeting the somatic and germline genes (Fig. 2A, B, and C),
suggesting that the core RNAi machinery to respond to exogenous long dsRNA was not
altered in these mutants. We also verified that all of these eight mutants supported
replication of the recombinant FHV RNA1 and transcription of its subgenomic RNA at
levels readily detectable by Northern blot hybridization (Fig. S1C).
We further sequenced the total small RNAs of the eight mutants proficient in
exogenous RNAi after OrV infection to determine if any of these mutants exhibited
defects in the production of the primary or secondary viral siRNAs (vsiRNAs). The small
FIG 2 The isolated mutants are defective in exogenous and/or antiviral RNAi. (A to C) Susceptibility of the isolated mutants to exogenous RNAi to target the
somatic (dpy-7 [A] and unc-22 [B]) and germline (pos-1 and pop-1 [C]) genes. Shown are the percentage of dumpy animals after RNAi of dpy-7 (pink) or of viable
animals after RNAi of pos-1 (blue) or pop-1 (gray), respectively. RNAi of unc-22 (B) caused twitching (gray) or paralysis (purple). The N2;FR1gfp (irSi18) worm strain
was used as the control. Mutants exhibiting similar patterns as rde-1 worms are marked with asterisks. (D) Size distribution, polarity, and the 5=-terminal
nucleotide of virus-derived small RNAs sequenced by the 5=-P-independent protocol from N2 and mutant worms 5 days after infection with Orsay virus. The
relative abundance of different-size sense vsiRNAs (top) is shown as the proportion of sense vsiRNAs, whereas that of antisense vsiRNAs (bottom) is presented
as the proportion of total vsiRNAs. The abundance of the total 21- to 24-nt vsiRNAs in each sequenced small RNA library is given (in parentheses).
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RNAs captured by the 5=-P-independent protocol include both the primary and sec-
ondary vsiRNAs containing 5= mono- and triphosphates, respectively (14). As controls,
we also sequenced the small RNAs from wild-type N2 and rrf-1 mutant worms infected
with OrV, and the properties of the vsiRNA reads mapped to the genome of OrV (11)
are presented in Fig. 2D according to the format used by Miska and colleagues (14). The
antisense vsiRNAs produced by N2 worms exhibited the known properties of secondary
siRNAs with strong preference for both 5=-terminal guanosine (blue bars) and 22 nt,
whereas the sense vsiRNAs were enriched for 23 nt without a clear 5=-terminal
nucleotide preference (Fig. 2D). In contrast, 23-nt RNAs were the most abundant for
both the sense and antisense vsiRNAs in rrf-1 mutant worms, and neither the antisense
nor sense vsiRNAs showed a preference for 5=-terminal guanosine (Fig. 2D). Consistent
with the published data (14), therefore, deep sequencing of the total small RNAs cloned
by the 5=-P-independent protocol revealed production of a typical population of the
primary vsiRNAs in rrf-1 mutant worms and of a mixed population of the primary and
secondary vsiRNAs in N2 worms. We found that all of the eight mutants produced
vsiRNAs in the size range of 21 to 24 nt with the relative abundance of vsiRNAs in these
mutants (1.57% to 9.21%) being higher than that in N2 worms (1.11%) (Fig. 2D).
However, the prevalence of both the 23-nt primary vsiRNAs and the 22G antisense
secondary vsiRNAs was markedly reduced in ucr2, ucr3, ucr4, and ucr6 mutants com-
pared to N2 worms or the remaining mutants (Fig. 2D), suggesting specific defects in
antiviral RNAi. These results together indicate the feasibility of discovering the genes
involved in both exogenous and antiviral RNAi by the FHV replicon-based genetic
screen.
Identification of four novel alleles of drh-1 by a mapping strategy based on
whole-genome resequencing. We mapped the causal mutations in ucr2, ucr3, ucr4,
and ucr6 mutants defective in antiviral RNAi but proficient in exo-RNAi by a mapping-
by-sequencing strategy (see Text S1 in the supplemental material). Unexpectedly,
defective antiviral RNAi in all of the four mutants was caused by a single nucleotide
polymorphism (SNP) in drh-1 and restored by transgenic expression of wild-type DRH-1
protein (see Fig. S2, S3, and S4 in the supplemental material). Specifically, whereas the
drh-1(ucr3) missense allele (A72T) was located in the worm-specific N-terminal domain,
the drh-1(ucr4) missense allele altered the proline residue (Pro966) in the C-terminal
domain that is conserved in DRH-3 and mammalian RIG-I/MDA5. The drh-1(ucr6)
nonsense mutation results in a premature translational termination of DRH-1 to remove
the entire C-terminal domain. Finally, the drh-1(ucr2) lesion led to the use of an
alternative intron splice site, resulting in an in-frame deletion of 30 amino acids in the
Hel2i domain found only in the group of the dsRNA-activated ATPases.
Detection of abundant 23-nt vsiRNAs targeting the terminal regions of viral
genomic RNAs in drh-1 mutant worms. Identification of multiple alleles in the drh-1
gene from our unbiased genetic screen further supports an indispensable role of DRH-1
in antiviral RNAi in C. elegans revealed by previous studies (7, 14, 17). Curiously, we
noted a strong peak at 23 nt for both the sense and antisense vsiRNAs in all of our four
drh-1mutants (Fig. 2D), which was not detected previously in the drh-1(ok3495) mutant
infected with OrV (14). The absence of a distinct 23-nt peak among other nonspecific
sizes of OrV-derived small RNAs led to the conclusion that DRH-1 is required for the
initiation of an antiviral RNAi pathway to generate the primary vsiRNAs by Dicer (14).
This conclusion was in disagreement with a previous study from our group, which
detected accumulation of the vsiRNAs to target the replicating FHV RNA1 in drh-
1(tm1329) mutant worms by Northern blot hybridization (7). Thus, we sequenced the
small RNAs cloned by the 5=-P-independent protocol from OrV-infected drh-1(tm1329)
mutant worms to determine if drh-1(tm1329) mutant worms could produce vsiRNAs in
response to OrV infection. As shown in Fig. 2D, the drh-1(tm1329) mutant worms
produced a mixed population of the primary and secondary vsiRNAs highly similar to
those detected in ucr2, ucr3, ucr4, and ucr6 mutant worms.
We noted that the complete 5=- and 3=-terminal sequences of both OrV RNA1 and
RNA2 (11) were not available for the initial mapping of vsiRNAs (14). Thus, the
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population of the 23-nt vsiRNAs that we detected in drh-1 mutants might be derived
from these terminal regions of the OrV genomic RNAs. To test this idea, we examined
the distribution patterns of 23-nt vsiRNAs along the full-length genomic RNA1 and
RNA2 of OrV sequenced from infected N2, drh-1(ucr2), drh-1(ucr3), drh-1(ucr4), and
drh-1(ucr6) animals. Indeed, we found that in all four drh-1 mutants, abundant 23-nt
vsiRNAs in both positive and negative polarities were mapped to the 5=-terminal region
of both RNA1 and RNA2 and to the 3=-terminal region of only RNA2 (Fig. 3A), which is
847 nt shorter than RNA1 (11).
We next analyzed the published libraries of vsiRNAs cloned similarly using the
5=-P-independent protocol by Miska and colleagues from a panel of worm mutants
after OrV infection (14). In all of the three independent small RNA libraries from the
infected drh-1(ok3495) mutant animals, high densities of the 23-nt sense and antisense
vsiRNAs were found to target the 5=-terminal region of both OrV RNA1 and RNA2 and
the 3=-terminal region of RNA2 (Fig. 3B). In contrast, 23-nt vsiRNA hot spots were
randomly distributed across the terminal and internal regions of the two viral genomic
RNAs in rde-1, rde-4, rrf-1, and drh-3 mutant worms, all of which support high levels of
OrV replication because of defective antiviral RNAi, similarly to drh-1 mutant worms (7,
9, 14, 16, 17, 37).
We further divided the 23-nt vsiRNAs in each library into the terminal and internal
vsiRNAs according to whether or not they are mapped to the 5=-terminal 200-nt region
of both OrV RNA1 (3,421 nt) and RNA2 (2,574 nt) and the 3=-terminal 200-nt region of
RNA2 (11). We found that approximately 50% of the total 23-nt vsiRNAs in the seven
independent libraries cloned from distinct drh-1 mutants were terminal vsiRNAs
(Fig. 3C). In contrast, less than 12% of the total 23-nt vsiRNAs targeted the terminal
regions of OrV RNAs in N2 or rde-1, rde-4, rrf-1, or drh-3 mutant animals (Fig. 3C). These
findings showed that distinct drh-1 mutants accumulated abundant 23-nt vsiRNAs in
response to OrV infection. Together with our previous report (7), our results demon-
strate that DRH-1 is not essential for the biogenesis of the vsiRNAs induced in vivo by
either FHV replication or OrV infection.
The terminal vsiRNAs made by drh-1 mutant worms exhibit the signatures of
Dicer products. We further analyzed the properties of the terminal vsiRNAs in the
seven small RNA libraries cloned by the 5=-P-independent protocol from five distinct
drh-1 mutants after OrV infection. First, we examined the size distribution and the
5=-terminal nucleotide of the total 18- to 28-nt sense and antisense small RNAs mapped
to the 3=-terminal 200-nt region of OrV RNA 2 and the 5=-terminal 200-nt region of OrV
RNA1 and RNA2. The results showed that both of the 5=- and 3=-terminal viral small
RNAs from all of the libraries exhibited a strong preference for 22 to 24 nt in the size
range of Dicer products (Fig. 4, top panel in each library). Moreover, the terminal viral
23-nt RNAs were highly enriched for a 21-nt perfectly base-paired duplex with 2-nt 3=
overhangs (Fig. 4, bottom panel in each library). These findings indicate that the
terminal viral small RNAs made by drh-1 mutant worms are the primary vsiRNAs
processed by Dicer from the terminal viral dsRNA replicative intermediates. Consis-
tently, the 22- to 24-nt antisense vsiRNAs targeting the terminal regions did not show
a preference for 5=-terminal guanosine in all libraries, indicating that these terminal
vsiRNAs are not the secondary vsiRNAs. Interestingly, several of the terminal antisense
vsiRNA populations exhibited modest enrichments for 5=-terminal uracil (Fig. 4, top
panel in each library), which was similar to worm microRNAs (miRNAs) and to the
influenza A virus vsiRNAs produced by human Dicer in somatic cells (38).
Dicer-dependent miRNAs and primary siRNAs contain 5=-monophosphates and are
selectively captured by the 5=-P-dependent protocol (39). Thus, we analyzed the
published small RNA libraries cloned from OrV-infected N2 and drh-1(ok3495), rde-1,
drh-3, and drh-1(ok3495); drh-3mutant animals by the 5=-P-dependent protocol (14). We
found that the terminal vsiRNAs did not accumulate to higher densities than the
internal vsiRNAs in N2 or rde-1 or drh-3mutant animals (Fig. 5A and C). In contrast, high
densities of 23-nt vsiRNAs were mapped to the 5=-terminal regions of OrV RNA1 and
RNA2 as well as to the 3=-terminal region of OrV RNA2 in both drh-1(ok3495) and
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FIG 3 drh-1 mutants produce highly abundant 23-nt vsiRNAs to target the terminal regions. (A and B)
Mapping of 23-nt sense (red) and antisense (blue) vsiRNAs to the full-length genomic RNAs of OrV cloned
from N2 and mutant animals by the 5=-P-independent protocol. The relative abundance was calculated
as the 23-nt vsiRNA reads per million miRNAs. (C) Percentage of 23-nt vsiRNAs mapped to the three
terminal regions (including the 3=-terminal 200-nt region of RNA2 and the 5=-terminal 200-nt regions
(Continued on next page)
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drh-1(ok3495); drh-3 animals (Fig. 5A). Thus, the same three terminal regions of the viral
genomic RNAs were preferentially targeted by high densities of 23-nt vsiRNAs as found
for the 23-nt vsiRNAs cloned by the 5=-P-independent protocol (Fig. 3A). Specifically,
more than 50% of the total 23-nt vsiRNAs were mapped to these terminal 200-nt
regions of the viral genomic RNAs (Fig. 5C). We found that the total sense and antisense
small RNAs mapped to these terminal regions of OrV RNA1 and RNA2 exhibited a
strong preference for 22 to 24 nt in the size range of Dicer products in both the single
and double mutants (Fig. 5B). Moreover, the 23-nt terminal vsiRNAs were highly
enriched for the 21-nt perfectly base-paired duplex with 2-nt 3= overhangs (Fig. 5A,
right panel). Therefore, examining the total small RNAs captured by the 5=-P-dependent
protocol also revealed the production of Dicer-dependent vsiRNAs in drh-1(ok3495)
animals after OrV infection.
Detection of Dicer-dependent biogenesis of vsiRNAs in drh-1 mutant animals indi-
cates that DRH-1 mediates antiviral RNAi at a step after the host immune detection and
the subsequent Dicer-mediated processing of the viral dsRNA replicative intermediates.
Notably, the abrupt decrease in the density of the primary vsiRNAs from the terminal
regions to the internal regions of the viral genomic RNAs was observed only in drh-1
mutant worms, not in N2 or rde-1, rde-4, or drh-3mutant worms (Fig. 3 and 5). Thus, the
presence of DRH-1 in the wild-type and mutant worms appeared to reduce the
production of the terminal vsiRNAs and/or enhance Dicer-dependent production of
the primary vsiRNAs to target the internal regions of the viral genomic RNAs.
Genetic requirements for the biogenesis of the DRH-1-independent terminal
vsiRNAs. We further analyzed the total small RNAs mapped to the complete genome
of OrV in the total small RNA libraries cloned by the 5=-P-independent protocol from
OrV-infected double mutants that combine drh-1(ok3495) with rde-1, rde-4, or drh-3 (14).
We found that viral small RNAs mapped to the 5=- and 3=-terminal regions of the OrV
genome exhibited a strong preference for 22 and 23 nt in drh-1; rde-1 and drh-1; drh-3
double mutants (Fig. 6A), similarly to those cloned from each individual single mutant
(Fig. 4; see also Fig. S5 in the supplemental material). High densities of the 23-nt
vsiRNAs from both of the worm double mutants were mapped to the 5=-terminal region
of OrV RNA1 and RNA2 as well as to the 3=-terminal region of RNA2 (Fig. 6B). Moreover,
the terminal 23-nt vsiRNAs were highly enriched for the 21-nt perfectly base-paired
duplex with 2-nt 3= overhangs (Fig. 6C), the density of the terminal vsiRNAs was clearly
higher than that of the internal vsiRNAs (Fig. 6D), and the antisense vsiRNAs targeting
the terminal regions did not exhibit a preference for 5=-terminal guanosine (Fig. 6A) in
these two worm mutants. Thus, drh-1; rde-1 and drh-1; drh-3 mutants produced a
population of the terminal primary vsiRNAs indistinguishable from those detected in
distinct drh-1 single mutants in response to OrV infection, indicating that neither RDE-1
nor DRH-3 may play a role in the biogenesis of the terminal primary vsiRNAs.
In contrast, the viral small RNAs mapped to the terminal regions of the OrV genome
in drh-1(ok3495); rde-4 double mutant animals were predominantly positive strands,
exhibited no preference in the size range of Dicer products (Fig. 6A), and were not more
abundant than those mapped to the internal regions of the OrV genome (Fig. 6D),
unlike those cloned from either drh-1 or rde-4 single mutant animals (Fig. 4; Fig. S5).
Thus, the terminus-derived small RNAs accumulated in the drh-1(ok3495); rde-4 double
mutant were similar to those mapped to the remaining regions of the OrV genome (14)
and did not exhibit properties expected for Dicer products, indicating an essential role
for RDE-4 in the biogenesis of the terminal primary vsiRNAs in the absence of DRH-1.
Together, our findings indicate that the terminal vsiRNAs produced in mutant animals
defective in drh-1 function are dependent on DCR-1 and RDE-4 but independent of
RDE-1 and DRH-3.
FIG 3 Legend (Continued)
from both RNA1 and RNA2) in N2 and mutant animals. The libraries from drh-1(ok3495), rrf-1, rde-4, rde-1,
and drh-3 in panels B and C were from previously published data (14).
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DISCUSSION
In this study, we developed a small-animal model for forward genetic screens by
chemical mutagenesis to identify genes required for antiviral RNAi in C. elegans. We
isolated 13 viable mutants that supported markedly enhanced in vivo accumulation of
FIG 4 The terminal vsiRNAs cloned by the 5=-P-independent protocol from drh-1 mutants exhibit the signatures of Dicer
products. Size distribution, polarity, and the 5=-terminal nucleotide of the virus-derived small RNAs from OrV-infected drh-1
mutant worms mapped to the 5=-terminal 200-nt regions of both RNA1 and RNA2 (top, left) or to the 3=-terminal 200-nt region
of RNA2 (top, right). Computing the total pairs of the 23-nt virus small RNAs mapped to the three terminal regions with
different lengths of base pairing as described previously (41) revealed strong enrichment of canonical vsiRNA pairs (2 peak)
with 2-nt 3= overhangs (bottom). The libraries from drh-1(ok3495) were published previously (14).
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a mutant FHV replicon defective in the suppression of antiviral RNAi due to the genetic
inactivation of its VSR. Notably, the isolated mutants were all more susceptible than N2
worms to the infection by OrV and included five mutants defective in RNAi induced by
synthetic long dsRNA, demonstrating the potential of the FHV replicon approach to
studying antiviral RNAi in C. elegans. We show that EMS-induced mutations can be
mapped and cloned by whole-genome sequencing of pooled F2 progeny from a single
backcross with the parental strain even though the phenotypic penetrance is incom-
plete. Notably, the causal mutation in all of the four mutants defective in antiviral RNAi
but proficient in exogenous RNAi was mapped to independent single nucleotide
substitutions in the drh-1 gene, further supporting a central role of the host protein in
antiviral RNAi as indicated by previous studies (7, 14, 17).
FIG 5 The terminal vsiRNAs cloned by the 5=-P-dependent protocol from drh-1 mutants exhibit the
signatures of Dicer products. (A) Mapping of the 23-nt sense (red) and antisense (blue) vsiRNAs cloned from
N2 and mutant animals by Ashe et al. (14) to the genomic RNAs of OrV (left panel) and the enrichment of
the 23-nt vsiRNAs mapped to the three terminal regions for pairs of canonical vsiRNAs with 2-nt 3=
overhangs (2 peak, right panel). The relative abundance was calculated as the vsiRNA reads per million
miRNAs. (B) Size distribution, polarity, and the 5=-terminal nucleotide of total vsiRNAs from the same
libraries shown in panel A mapped to the 3=-terminal 200-nt region of RNA2 and to the 5=-terminal 200-nt
regions of both RNA1 and RNA2. The relative abundance of the different-size sense (top) and antisense
(bottom) vsiRNAs is shown as the proportion of total vsiRNAs. (C) Percentage of the total 23-nt vsiRNAs
mapped to the three terminal regions of OrV RNA1 and RNA2 from the same libraries shown in panel A.
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We discovered an abundant population of vsiRNAs targeting the terminal regions of
OrV genome in distinct drh-1 mutants, which escaped detection in a previous analysis
possibly because the complete genome sequence of OrV was unavailable for mapping
vsiRNAs at the time of the study (14). These vsiRNAs target the 5=-terminal regions of
both RNA1 and RNA2 as well as the 3=-terminal region of only RNA2, contain 5=-
monophosphates, exhibit a size preference in the range of Dicer products, and are
highly enriched for canonical siRNA duplexes with 2-nt 3= overhangs, indicating that
they correspond to the primary vsiRNAs processed by the single worm Dicer. Exami-
nation of the published libraries of small RNAs from drh-1 single and double mutants
infected with OrV (14) indicates that the terminal vsiRNAs are RDE-4 dependent but
independent of either RDE-1 or DRH-3, consistent with the known Dicer-dependent
biogenesis pathway for the primary exogenous and viral siRNAs (7, 14, 17, 22–25). FHV
replication in Drosophila melanogaster cells triggers the Dicer-2 processing of highly
abundant 5=-terminal dsRNA replicative intermediates of both RNA1 and RNA2, syn-
thesized during the initiation of the progeny positive-strand RNA replication from the
3= end of the negative-strand RNA templates (1, 40). A similar mechanism may be
responsible for the biogenesis of the 5=-terminal vsiRNAs in C. elegans. Detection of
abundant vsiRNAs to target only the 3=-terminal region of OrV RNA2 in worms (Fig. 3A,
5A, and 6B) suggests that RNA2 is perhaps more active than RNA1 as the template for
FIG 6 Genetic requirements for biogenesis of the drh-1-independent vsiRNAs. (A) Size distribution, polarity,
and the 5=-terminal nucleotide of total small RNAs cloned by the 5=-P-independent protocol by Ashe et al.
(14) that were mapped to the 3=-terminal 200-nt region of RNA2 and the 5=-terminal 200-nt regions from
both RNA1 and RNA2. (B) Mapping of the 23-nt sense (red) and antisense (blue) vsiRNAs to the genomic
RNAs of OrV obtained from two double mutant animals from the same libraries shown in panel A. (C) Strong
enrichment of the 23-nt vsiRNAs from the three terminal regions for pairs (2 peak) of canonical vsiRNAs
with 2-nt 3= overhangs in the two double mutant worms by computing total pairs of 23-nt vsiRNAs with
different lengths of base pairing as described previously (41). (D) Percentage of the total 23-nt vsiRNAs
mapped to the three terminal regions from the same libraries shown in panel A.
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the negative-strand RNA synthesis by the viral replicase. Our findings together show
that the essential function of DRH-1 in antiviral RNAi occurs at a step after the initial
Dicer-dependent processing of the viral dsRNA replicative intermediates into the
primary vsiRNAs. Thus, detection of the primary vsiRNAs, the immediate product after
immune sensing of viral dsRNA by the RNAi machinery, allows us to conclude that
DRH-1 does not act as the immune receptor of antiviral RNAi. This is in contrast to the
receptor function of mammalian RLRs in innate immunity against RNA virus infections
(30, 31).
Recent studies indicate that Dicer proteins, mammalian RLRs, and worm DRH-1/
DRH-3 are duplex RNA-activated ATPases (34). We found that Dicer-dependent primary
vsiRNAs produced in distinct drh-1 mutant worms were mapped predominantly to the
terminal regions of the viral genomic RNAs. The drh-1 mutants examined in this work
included drh-1(ucr2), drh-1(ucr4), and drh-1(ucr6) mutants that contained independent,
EMS-induced mutations in the specific domains of DRH-1 that are highly conserved
among the duplex RNA-activated ATPases (34). In contrast, the hot spots of the primary
vsiRNAs were randomly distributed across the viral genomic RNAs in either wild-type
N2 worms or RNAi-detective mutants such as rde-1, rde-4, rrf-1, and drh-3 mutants.
These findings suggest that DRH-1 acts to reduce the biogenesis of the terminal
primary vsiRNAs and/or enhance Dicer-dependent production of the primary vsiRNAs
to target the internal regions of the viral genomic RNAs in C. elegans. Given that RIG-I
can translocate on long dsRNA powered by ATP hydrolysis (35), a similar translocase
activity predicted for DRH-1 (34) would facilitate the rapid translocation of the known
DCR-1/RDE-4/DRH-1 complex (20) on the viral dsRNA precursors. Presumably, this
enzymatic activity of DRH-1 would allow the processing of the internal regions of the
viral dsRNA into primary vsiRNAs to ensure the subsequent production of the second-
ary vsiRNAs at levels sufficiently high to inhibit the replication of OrV and FHV. It is
known that cellular mRNAs are targeted for efficient RNAi by the vsiRNAs made in drh-1
mutants (15, 17), indicating that the enhanced biogenesis of vsiRNAs by DRH-1 confers
a specific antiviral function in C. elegans. Recent studies have demonstrated Dicer-
dependent processing of viral dsRNA replicative intermediates into vsiRNAs in mam-
mals (38, 41, 42). Thus, it would be interesting to determine if RLRs and interferon
signaling play a role in the biogenesis of vsiRNAs targeting RNA virus infections in
mammals.
MATERIALS AND METHODS
Worm maintenance and genetics. C. elegans genetics and culture, heat induction of the recombi-
nant RNA1 transgene of FHV (FR1gfp), and Northern blot detection of FHV RNA1 and RNA3 were as
described previously (6, 7). The phsp-16.41::FR1gfp transgene used to generate a single-copy insertion in
this study (see Text S1 in the supplemental material) was a derivative of the phsp-16.41::FR1gfp transgene
previously described (6, 7) by replacing the self-cleaving ribozyme in the original construct with the
ribozyme from hepatitis delta virus. The resultant worm strain, designated N2;FR1gfp (N2;irSi18), was
subjected to EMS mutagenesis using standard techniques (36). FHV replication was induced at the L4
stage, and F2 worms expressing any GFP were transferred individually to their own plate and left to lay
eggs. Each mutant selected was backcrossed to N2;irSi18 at least four times, and the phenotype of the
induced viral GFP expression was verified two additional times.
Preparation of whole-genome libraries and mapping by genome resequencing. One hundred
F2s from a backcross of each mutant to the N2;FR1gfp parent were transferred to individual plates and
given time to lay eggs. Each F2 was used in single-worm DNA extractions to be genotyped later. Once
the F3s reached the L4 stage, the segregation of their viral GFP expression phenotype was scored to
determine if the F2 was wild type or a heterozygous or homozygous mutant. The F3 populations from
20 homozygous mutant F2s and 20 homozygous wild-type F2s were pooled, and DNA was extracted
using the Gentra Puregene kit (Qiagen). The DNA was sheared using a Bioruptor (30 s on, 30 s off, for
15 min). To construct libraries for sequencing, 1 g from each pool was used to generate a library using
the PCR-free TruSeq DNA kit (Illumina). The samples were multiplexed to have six libraries in each lane
for paired-end sequencing of 100-nt reads on an Illumina 2500 sequencer. Mutant and wild-type libraries
for ucr2 were constructed using the NEXTflex PCR-free DNA library preparation kit for Illumina (Bioo
Scientific), which gave lower genome coverage than the other three mutants. Mapping of the causal
mutations in the four mutants by whole-genome sequencing and computational analysis was essentially
as described previously (43).
Preparation and analysis of small RNA libraries. Infection of N2 and mutant worms with OrV was
done as described previously (9, 14). Extraction of small RNAs and removal of the 5=-triphosphate groups
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from the secondary small RNAs by RNA 5=-polyphosphatase (RPP) were done as described previously (39).
RPP-treated, purified small RNAs were used in the generation of small RNA libraries using the TruSeq
small RNA sample preparation kit (Illumina). Samples were multiplexed and sequenced on an Illumina
2500 sequencer. The analysis of small RNAs was done as described previously (41). We removed the reads
from each library that aligned with zero mismatches to the sense strand of structural small RNAs (25). The
resultant nonstructural small RNA reads were used in the following analyses. The nonstructural small
RNAs were aligned to C. elegans miRNAs obtained from WormBase (WS240) and used to normalize
vsiRNA reads. Small RNA reads were aligned to the OrV genome (GenBank identifiers [IDs] HM030970.2
and HM030971.2), allowing zero mismatches essentially as described previously (41). For RPP-treated
libraries, the sense vsiRNAs were normalized to the total sense vsiRNAs, whereas antisense reads were
normalized to total vsiRNAs as described previously (14).
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